Cargando…

Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature

BACKGROUND: Sintilimab is an immune checkpoint inhibitor (ICI). It can induce immune-related Adverse Events (irAEs). Severe adverse skin reactions are rare, but the mortality rate is high. We report the first case of successful treatment of adverse skin reactions using traditional Chinese medicine (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Juan, Ma, Na, Qiao, Wei-Li, Liu, Ke-Qin, Liu, Dai-Wei, Wang, Yu, Qiao, Ting-Ting, Hao, Xiu-Qing, Zheng, Mao-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843412/ https://www.ncbi.nlm.nih.gov/pubmed/36660611 http://dx.doi.org/10.21037/atm-22-5925

Ejemplares similares

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer
por: Cheng, Rihua, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
por: Liu, Linlin, et al.
Publicado: (2023)

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
por: Liu, Zichang, et al.
Publicado: (2023)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma
por: Dai, Lei, et al.
Publicado: (2021)

Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review
por: Huang, Wenying, et al.
Publicado: (2023)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors
por: Huang, Nana, et al.
Publicado: (2022)

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
por: Wang, Ting, et al.
Publicado: (2023)

Sintilimab-induced autoimmune diabetes: A case report and review of the literature
por: Yang, Jing, et al.
Publicado: (2022)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

Network pharmacology analysis of the mechanism of Huisheng oral liquid in the treatment of lung cancer
por: Yan, Juan, et al.
Publicado: (2022)

Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review
por: Zhang, Mei, et al.
Publicado: (2023)

Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma—A Report of Two Cases
por: Mei, Xinkuan, et al.
Publicado: (2022)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review
por: Yin, Cunli, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report
por: Li, Haoqian, et al.
Publicado: (2023)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

Osteoblastic Bone Reaction Developing During Treatment With Sintilimab and Bevacizumab in a Patient With KRAS(G12V)-Mutant Lung Adenocarcinoma
por: Chen, Chang Jun, et al.
Publicado: (2023)

Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review
por: Wang, Min, et al.
Publicado: (2022)

Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review
por: Liu, Xin, et al.
Publicado: (2023)

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress
por: Ji, Hongxiang, et al.
Publicado: (2022)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer
por: Liang, Xiaoyan, et al.
Publicado: (2021)

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
por: Jiang, Haiping, et al.
Publicado: (2020)

A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma
por: Gong, Yinhua, et al.
Publicado: (2023)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain
por: Yan, Juan, et al.
Publicado: (2023)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
por: Shen, Jian, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
por: Shao, Taihang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vqll6kamni7vst5pmbbc4v9kh0